Histone deacetylase inhibitors open new doors in cancer therapy

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 1139-1144

  McLaughlin, Fiona ^a   La Thangue, Nicholas B ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BioAlliance Pharma   (France)

Author keywords

Acetylation; Cell cycle; Chromatin; Histone deacetylase; Transcription

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; ANTINEOPLASTIC AGENT; BUTYRIC ACID; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PIVALOYLOXYMETHYL BUTYRATE; PYROXAMIDE; SB 379872 A; SB 429201; SB 556629; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GROWTH REGULATION; HUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TUMOR CELL;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; DRUG DESIGN; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 4143140016     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.05.034     Document Type: Conference Paper

References (46)

1. Li J.L. A model for chromatin structure. Nucl. Acid Res. 8:1975;1275-1289
2. Jenuwein T., Allis C.D. Translating the histone code. Science. 293:2001;1074-1080
3. Pogo B.G.T., Allfrey V.G., Mirsky A.E. RNA synthesis and histone acetylation during the course of gene activation in lymphocytes. Proc. Natl. Acad. Sci. 55:1966;805-812
4. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 272:1996;371-372
5. Brachmann C.B., Sherman J.M., Devine S.E., Camerson E.E., Pillus L., Boeke J.D. The SIR 2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Gen. Dev. 9:1995;2888-2902
6. Furukawa Y., Kawakami T., Sudo K., Inazawa J., Matsumine A., Akiyama T., et al. Isolation and mapping of a human gene (PRD3L1) that is homologous to PRD3, a transcription factor in Saccharomyces cerevisiae. Cytogenet Cell Genet. 73:1996;130-133
7. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature. 401:1999;188-193
8. Cheng H.L., Mostoslavsky R., Saito S., Manis J.P., Gu Y., Patel P., et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. 100:2003;10794-10799
9. De Ruijter A.J.M., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B.P. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370:2003;737-749
10. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:2002;479-488
11. Dequiedt F., Kasler H., Fischle W., Kiermer V., Verdin E. Weinstein, HDAC7, a thymus-specific Class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity. 18:2003;687-698
12. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., et al. Phase I clinical trial of histone deacetylase inhibitors: suberoylanilide hydroxamic acid administered intravenously. Clin. Can. Res. 9:2003;3578-3588
13. Plumb J., Finn P.W., Williams R.J., Bandara M., Romero M.R., Watkins C.J., et al. Brown, pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Theor. 2:2003;721-728
14. Blaheta R.A., Nau H., Michaelis M., Cinatlt J. Jr. Valproate and valproate-analogues: potent tools to fight against cancer. Curr. Med. Chem. 9:2002;1417-1433
15. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8:2002;718-728
16. Marshall J.L., Rizvi N., Kauh J., Dahut W., Figuera M., Kang M.H., et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Theor. Oncol. 2:2002;325-332
17. Colletti S.L., Myers R.W., Darkin-Rattray S.J., Gurnett A.M., Dulski P.M., Galuska S., et al. Broad spectrum antiprotozoal agents that inhibit histone deacetylase: structure-activity relationships of apicidin. Bioorg. Med. Chem. Lett. 11:2001;113-117
18. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., Horinouchi S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. 98:2001;87-92
19. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumors. Proc. Natl. Acad. Sci. 96:1999;4592-4597
20. Prakash S., Foster B.J., Meyer M., Wozniak A., Heilbrun L.K., Flaherty L., et al. Chronic oral administration of CI-994. Invest New Drugs. 19:2001;1-11
21. McLaughlin F., Finn P., La Thangue N.B. The cell cycle, chromatin and cancer: mechanism based therapeutics come of age. Drug Disc Today. 8:2003;793-802
22. Kim Y.B., Ki S.W., Yoshida M., Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibio. s53:2000;1191-1200
23. Kim J.S., Lee S., Lee T., Trepel J.B., Lee Y.-W. Transcriptional activation of p21WAF1/CIP1 by Apicidin, a novel histone deacetylase inhibitor. Biochem. Biophys. Res. Commun. 281:2001;866-871
24. Finzer P., Soto U., zur Hausen H., Rosl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene. 20:2001;4768-4776
25. Huang L., Pardee A.B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 6:2000;849-866
26. Martinez-Balbas M.A., Bauer U.-M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F-1 activity by acetylation. EMBO J. 19:2000;662-671
27. Gu W., Roeder R.G. Activation of p53 sequence specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606
28. Chan H.M., Krstic-Demonacos M., Smith L., Demonacos C., La Thangue N.B. Acetylation control of the retinoblastoma tumour suppressor protein. Nat. Cell. Biol. 3:2001;667-674
29. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gen. Express. 5:1996;245-253
30. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Theor. 2:2003;151-163
31. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. 101:2004;540-545
32. Yu C., Rahmani M., Almerara J., Subler M., Krystal G., Conrad D., et al. Histone deacetylase inhibitors promote ST1571-mediated apoptosis in ST1571-sensitive and -resistant Bcr/Abl+ Human Myeloid leukaemia cells. Cancer Res. 63:2003;2118-2126
33. Nimmanapalli R., Fuino L., Stobaugh C., Richon V.M., Bhalla K. Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells. Blood. 101:2003;3236-3239
34. Jang E.R., Lim S.-J., Lee E.S., Jeong G., Kim T.-Y., Bang Y.-J., et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene. 23:2004;1724-1736
35. Keen J.C., Yan L., Mack K.M., Pettit C., Smith D., Sharma D., et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res. Treat. 81:2003;177-186
36. Zhu W.G., Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anti-Cancer Agents. 3:2003;187-199
37. Curtin M., Glaser K. Histone deacetylase inhibitors: the abbott experience. Curr. Med. Chem. 10:2003;2373-2392
38. Johnstone R.W. Histone deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discovery. 1:2002;287-299
39. Kao H.Y., Verdel A., Tsai C.C., Simon C., Juguilon H., Khochbin S. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J. Biol. Chem. 276:2001;47496-47507
40. Bertos N.R., Wang A.H., Yang X.J. Class II histone deacetylases: structure, function, and regulation. Biochem. Cell. Biol. 79:2001;243-252
41. Hofmann GA, Hu E, Winkler JD, Zhang XL, Martin JD, Liu W-S, Carr SA, Meek T, Macarron R. A novel homogenous fluorescent method to monitor histone deacetylase activity. In: Proceedings of the Sixth Annual Conference of the Society for Bimolecular Screening, September 6-9. Vancouver: Canada Society for Biomolecular Screening, Danbury, CT. p. 209.
42. Hu E., Dul E., Sung C.M., Chen Z., Kirkpatrick R., Zhang G.F., et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Theor. 2:2003;720-728
43. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nakajima H., Tanaka A., et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62:2002;4616-4621
44. Voelter-Mahlknecht S., Mahlknecht U. Cloning and structural characterization of the human histone deacetylase 6 gene. Int. J. Mol. Med. 12:2003;87-93
45. Kawaguchi Y., Kovacs J.J., McLaurin A., Vance J.M., Ito A., Yao T.P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 115:2003;727-738
46. Wong J.C., Hong R., Schreiber S.L. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J. Am. Chem. Soc. 125:2003;5586-5587